REGN


Regeneron Inks Deal to Supply Additional 1.25M COVID-19 Antibody Doses to US

Regeneron Pharmaceuticals has signed an agreement with the U.S.

Regeneron Halts Covid-19 Trial For High-Flow Oxygen Patients; Shares Fall

Regeneron Pharmaceuticals (REGN) has revealed that the independent data monitoring committee (IDMC) has advised it to modify its current REGN-COV2 antibody cocktail treatment trials …

Regeneron Scores FDA Nod For Ebola Treatment

Regeneron announced that the US Food and Drug Administration (FDA) has approved its Inmazeb anti-viral antibody as a first-of-its-kind treatment for Ebola virus infection …

Sanofi, Regeneron’s Dupixent Significantly Reduces Children’s Asthma Attacks

Sanofi (SNYNF) and Regeneron have announced that a pivotal Phase 3 trial of Dupixent (dupilumab) met its primary and all key secondary endpoints in children …

Regeneron Files For Emergency Use Nod Of Covid-19 Antibody Cocktail; Shares Rise

Shares in Regeneron advanced 3.5% in Wednesday’s extended market session after the company filed for Emergency Use Authorization (EUA) with the US Food …

Regeneron Up 4% As Covid-19 Cocktail Lowers Viral Levels; Analyst Says Hold

Shares in Regeneron Pharmaceuticals are advancing 4.4% in Wednesday’s pre-market trading after the company disclosed that its investigational two-antibody cocktail, REGN-COV2, lowered viral …

Sanofi, Regeneron’s Libtayo Delivers Positive Results In Pivotal Lung Cancer Trial

Sanofi (SNYNF) and Regeneron have announced positive pivotal trial data for the investigational use of PD-1 inhibitor Libtayo (cemiplimab) in first-line locally advanced …

Regeneron, Sanofi’s Dupixent Shows Sustained Asthma Benefits In 3-Yr Trial

Regeneron Pharmaceuticals (REGN) and Sanofi have announced new results from a Dupixent (dupilumab) Phase 3 open-label extension trial that showed the safety and efficacy …

Regeneron, Roche Team Up To Supply Covid-19 Antibody Cocktail To World

Regeneron Pharma (REGN) and Roche (RHHBY) have announced that they will work together to develop, manufacture and distribute REGN-COV2, Regeneron’s investigational anti-viral antibody …

Regeneron Prices $1.25B Public Offering; Analyst Cautious On Valuation

Regeneron Pharmaceuticals (REGN) has now announced the pricing of an underwritten offering of $1.250 billion aggregate principal amount of senior unsecured notes due …

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts